OASIS-6 Trial

Summary: Patients with acute MI randomized to received fondaparinux with either heparin or fondaparinux with placebo. There was also subgroups of fondaparinux versus no fondaparinux (placebo) and fondaparinux versus unfractionated heparin.

Patients not undergoing PCI had significant reduction in death/reinfarction with fondaparinux versus unfractionated heparin. This benefit was not seen when the patient underwent PCI. There was a significant increase in catheter thrombosis in the group undergoing PCI.

There was a decrease in death/reinfarction in patients receiving fondaparinux versus placebo.

Original Publication:

JAMA. 2006 Apr 5;295(13):1519-30.

Eponym: Organization to Assess Strategies in Ischemic Syndromes